| |||
Names | |||
---|---|---|---|
Preferred IUPAC name
2-(2,5-Dimethoxyphenyl)ethan-1-amine | |||
Other names
2,5-Dimethoxy-phenethylamine
| |||
Identifiers | |||
3D model (
JSmol)
|
|||
ChEMBL | |||
ChemSpider | |||
ECHA InfoCard | 100.153.556 | ||
PubChem
CID
|
|||
UNII | |||
CompTox Dashboard (
EPA)
|
|||
| |||
| |||
Properties | |||
C10H15NO2 | |||
Molar mass | 181.23 g/mol | ||
Melting point | 138 to 139 °C (280 to 282 °F; 411 to 412 K) ( hydrochloride) | ||
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
2C-H (2,5-dimethoxyphenethylamine) is a lesser-known substituted phenethylamine of the 2C family.
2C-H was first synthesized in 1932 by Johannes S. Buck. [1]
2C-H is used as a precursor in the synthesis of other substituted phenethylamines such as 2C-B, 2C-I, and 2C-N. [2] 2C-H has been found in trace amounts by the DEA's south central laboratory in tablets that were suspected of containing MDMA.[ citation needed]
There is no record of 2C-H trials in humans, as it would likely be destroyed by monoamine oxidase enzymes before causing any significant psychoactive effects. [2] In the book PiHKAL, Alexander Shulgin lists both the dosage and duration of 2C-H effects as unknown. [2] Very little data exists about the pharmacological properties, metabolism, and toxicity of 2C-H.
2C-H exhibits agonist activity in vitro at human trace amine associated receptor 1 expressed in RD-HGA16 CHO-K1 cells coexpressed with Galpha16 protein assessed as internal calcium mobilization. [3] 2C-H was found to be inactive in NCI In Vivo Anticancer Drug Screens for tumor model L1210 Leukemia. [3] It was found to be an active Alpha-1 adrenergic receptor agonist in rabbit ear arteries. [3] It has binding affinity towards 5-HT2C and 5-HT2A receptors in rats. [3] It features competitive antagonist activity at 5-HT serotonin receptor in Sprague-Dawley rat stomachs. [3] It exhibits binding affinity against rat 5-hydroxytryptamine 2C receptors using [3H] mesulergine as a radioligand. [3]
As of October 31, 2016; 2C-H is a controlled substance (Schedule III) in Canada. [4]
As of July 9, 2012, 2C-H is a Schedule I controlled substance in the United States, under the Synthetic Drug Abuse Prevention Act of 2012. [5] 2C-H's DEA Drug Code is 7517.
| |||
Names | |||
---|---|---|---|
Preferred IUPAC name
2-(2,5-Dimethoxyphenyl)ethan-1-amine | |||
Other names
2,5-Dimethoxy-phenethylamine
| |||
Identifiers | |||
3D model (
JSmol)
|
|||
ChEMBL | |||
ChemSpider | |||
ECHA InfoCard | 100.153.556 | ||
PubChem
CID
|
|||
UNII | |||
CompTox Dashboard (
EPA)
|
|||
| |||
| |||
Properties | |||
C10H15NO2 | |||
Molar mass | 181.23 g/mol | ||
Melting point | 138 to 139 °C (280 to 282 °F; 411 to 412 K) ( hydrochloride) | ||
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
2C-H (2,5-dimethoxyphenethylamine) is a lesser-known substituted phenethylamine of the 2C family.
2C-H was first synthesized in 1932 by Johannes S. Buck. [1]
2C-H is used as a precursor in the synthesis of other substituted phenethylamines such as 2C-B, 2C-I, and 2C-N. [2] 2C-H has been found in trace amounts by the DEA's south central laboratory in tablets that were suspected of containing MDMA.[ citation needed]
There is no record of 2C-H trials in humans, as it would likely be destroyed by monoamine oxidase enzymes before causing any significant psychoactive effects. [2] In the book PiHKAL, Alexander Shulgin lists both the dosage and duration of 2C-H effects as unknown. [2] Very little data exists about the pharmacological properties, metabolism, and toxicity of 2C-H.
2C-H exhibits agonist activity in vitro at human trace amine associated receptor 1 expressed in RD-HGA16 CHO-K1 cells coexpressed with Galpha16 protein assessed as internal calcium mobilization. [3] 2C-H was found to be inactive in NCI In Vivo Anticancer Drug Screens for tumor model L1210 Leukemia. [3] It was found to be an active Alpha-1 adrenergic receptor agonist in rabbit ear arteries. [3] It has binding affinity towards 5-HT2C and 5-HT2A receptors in rats. [3] It features competitive antagonist activity at 5-HT serotonin receptor in Sprague-Dawley rat stomachs. [3] It exhibits binding affinity against rat 5-hydroxytryptamine 2C receptors using [3H] mesulergine as a radioligand. [3]
As of October 31, 2016; 2C-H is a controlled substance (Schedule III) in Canada. [4]
As of July 9, 2012, 2C-H is a Schedule I controlled substance in the United States, under the Synthetic Drug Abuse Prevention Act of 2012. [5] 2C-H's DEA Drug Code is 7517.